Finding inhibitors and deciphering inhibitor-induced conformational plasticity in the Janus kinase via multiscale simulations

References

• C. Schindler, D.E. Levy, and T. Decker, JAK-STAT signaling: From interferons to cytokines, J. Biol. Chem. 282 (2007), pp. 20059–20063. doi:10.1074/jbc.R700016200.
   PubMed Web of Science ®Google Scholar
• K. Sanachai, P. Mahalapbutr, K. Choowongkomon, R.P. Poo-arporn, P. Wolschann, and T. Rungrotmongkol, Insights into the binding recognition and susceptibility of Tofacitinib toward Janus kinases, ACS Omega 5 (2020), pp. 369–377. doi:10.1021/acsomega.9b02800.
   PubMed Web of Science ®Google Scholar
• D.E. Levy and J.E. Darnell, STATs: Transcriptional control and biological impact, Nat. Rev. Mol. Cell Biol. 3 (2002), pp. 651–662. doi:10.1038/nrm909.
   PubMed Web of Science ®Google Scholar
• S.A. Oakes and F.R. Papa, The role of endoplasmic reticulum stress in human pathology, Annu. Rev. Pathol. 10 (2015), pp. 173–194. doi:10.1146/annurev-pathol-012513-104649.
   PubMed Web of Science ®Google Scholar
• A.V. Villarino, Y. Kanno, J.R. Ferdinand, and J.J. O’Shea, Mechanisms of Jak/STAT signaling in immunity and disease, J. Immunol. 194 (2015), pp. 21–27. doi:10.4049/jimmunol.1401867.
   PubMed Web of Science ®Google Scholar
• S.G. Sims and G.P. Meares, Janus kinase 1 is required for transcriptional reprograming of murine astrocytes in response to endoplasmic reticulum stress, Front. Cell Neurosci. (2019), pp. 13. Available at https://www.frontiersin.org/articles/10.3389/fncel.2019.00446.
   PubMed Web of Science ®Google Scholar
• L. Song and C. Schindler, Handbook of Cell Signaling, 2nd ed., R.A. Bradshaw and E.A. Dennis, eds., Academic Press, San Diego, 2010, pp. 2041–2048.
   Google Scholar
• Y. Tu, Y. Zhong, J. Fu, Y. Cao, G. Fu, X. Tian, and B. Wang, Activation of JAK/STAT signal pathway predicts poor prognosis of patients with gliomas, Med. Oncol. 28 (2011), pp. 15–23. doi:10.1007/s12032-010-9435-1.
   PubMed Web of Science ®Google Scholar
• C.S. Nicolas, M. Amici, Z.A. Bortolotto, A. Doherty, Z. Csaba, A. Fafouri, P. Dournaud, P. Gressens, G.L. Collingridge, and S. Peineau, The role of JAK-STAT signaling within the CNS, JAK-STAT 2 (2013), pp. e22925. doi:10.4161/jkst.22925.
   PubMedGoogle Scholar
• Z. Yan, S.A. Gibson, J.A. Buckley, H. Qin, and E.N. Benveniste, Role of the JAK/STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases, Clin. Immunol. 189 (2018), pp. 4–13. doi:10.1016/j.clim.2016.09.014.
   PubMed Web of Science ®Google Scholar
• M. Jain, M.K. Singh, H. Shyam, A. Mishra, S. Kumar, A. Kumar, and J. Kushwaha, Role of JAK/STAT in the neuroinflammation and its association with neurological disorders, Ann. Neurosci. 28 (2022), pp. 191–200. doi:10.1177/09727531211070532.
   Web of Science ®Google Scholar
• N.A. Lashgari, N.M. Roudsari, S. Momtaz, T. Sathyapalan, A.H. Abdolghaffari, and A. Sahebkar, The involvement of JAK/STAT signaling pathway in the treatment of Parkinson’s disease, J. Neuroimmunol. 361 (2021), pp. 577758. doi:10.1016/j.jneuroim.2021.577758.
   PubMed Web of Science ®Google Scholar
• N. Lesgidou, E. Eliopoulos, G.N. Goulielmos, and M. Vlassi, Insights on the alteration of functionality of a tyrosine kinase 2 variant: A molecular dynamics study, Bioinformatics 34 (2018), pp. i781–i786. doi:10.1093/bioinformatics/bty556.
   PubMed Web of Science ®Google Scholar
• T. Sato, T. Toki, R. Kanezaki, G. Xu, K. Terui, H. Kanegane, M. Miura, S. Adachi, M. Migita, S. Morinaga, T. Nakano, M. Endo, S. Kojima, H. Kiyoi, H. Mano, and E. Ito, Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukaemia accompanying Down syndrome, Br. J. Haematol. 141 (2008), pp. 681–688. doi:10.1111/j.1365-2141.2008.07081.x.
   PubMed Web of Science ®Google Scholar
• K. Ghoreschi, A. Laurence, and J.J. O’Shea, Janus kinases in immune cell signaling, Immunol. Rev. 228 (2009), pp. 273–287. doi:10.1111/j.1600-065X.2008.00754.x.
   PubMed Web of Science ®Google Scholar
• C.G. Mullighan, J. Zhang, R.C. Harvey, J.R. Collins-Underwood, B.A. Schulman, L.A. Phillips, S.K. Tasian, M.L. Loh, X. Su, W. Liu, M. Devidas, S.R. Atlas, I.M. Chen, R.J. Clifford, D.S. Gerhard, W.L. Carroll, G.H. Reaman, M. Smith, J.R. Downing, S.P. Hunger, and C.L. Willman, JAK mutations in high-risk childhood acute lymphoblastic leukemia, Proc. Natl. Acad. Sci. USA 106 (2009), pp. 9414–9418. doi:10.1073/pnas.0811761106.
   PubMed Web of Science ®Google Scholar
• A.T. Virtanen, T. Haikarainen, J. Raivola, and O. Silvennoinen, Selective JAKinibs: Prospects in inflammatory and autoimmune diseases, BioDrugs 33 (2019), pp. 15–32. doi:10.1007/s40259-019-00333-w.
   PubMed Web of Science ®Google Scholar
• C. Harrison, J.J. Kiladjian, H.K. Al-Ali, H. Gisslinger, R. Waltzman, V. Stalbovskaya, M. McQuitty, D.S. Hunter, R. Levy, L. Knoops, F. Cervantes, A.M. Vannucchi, T. Barbui, and G. Barosi, JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis, N. Engl. J. Med. 366 (2012), pp. 787–798. doi:10.1056/NEJMoa1110556.
   PubMed Web of Science ®Google Scholar
• K. Ghoreschi, M.I. Jesson, X. Li, J.L. Lee, S. Ghosh, J.W. Alsup, J.D. Warner, M. Tanaka, S.M. Steward-Tharp, M. Gadina, C.J. Thomas, J.C. Minnerly, C.E. Storer, T.P. LaBranche, Z.A. Radi, M.E. Dowty, R.D. Head, D.M. Meyer, N. Kishore, and J.J. O’Shea, Modulation of innate and adaptive immune responses by Tofacitinib (CP-690,550), J. Immunol. 186 (2011), pp. 4234–4243. doi:10.4049/jimmunol.1003668.
   PubMed Web of Science ®Google Scholar
• A. Mogul, K. Corsi, and L. McAuliffe, Baricitinib: The second FDA-approved JAK inhibitor for the treatment of rheumatoid arthritis, Ann. Pharmacother. 53 (2019), pp. 947–953. doi:10.1177/1060028019839650.
   PubMed Web of Science ®Google Scholar
• J.M. Parmentier, J. Voss, C. Graff, A. Schwartz, M. Argiriadi, M. Friedman, H.S. Camp, R.J. Padley, J.S. George, D. Hyland, M. Rosebraugh, N. Wishart, L. Olson, and A.J. Long, In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494), BMC Rheumatol 2 (2018), pp. 23.
   PubMedGoogle Scholar
• P. Wu, T.E. Nielsen, and M.H. Clausen, FDA-approvedsmall-molecule kinase inhibitors, Trends Pharmacol. Sci. 36 (2015), pp. 422–439. doi:10.1016/j.tips.2015.04.005.
   PubMed Web of Science ®Google Scholar
• N.K. Williams, R.S. Bamert, O. Patel, C. Wang, P.M. Walden, A.F. Wilks, E. Fantino, J. Rossjohn, and I.S. Lucet, Dissecting specificity in the Janus Kinases: The structures of JAK-Specific inhibitors complexed to the JAK1 and jak2 protein tyrosine kinase domains, J. Mol. Biol. 387 (2009), pp. 219–232. doi:10.1016/j.jmb.2009.01.041.
   PubMed Web of Science ®Google Scholar
• T.D. Goddard, C.C. Huang, E.C. Meng, E.F. Pettersen, G.S. Couch, J.H. Morris, and T.E. Ferrin, UCSF ChimeraX: Meeting modern challenges in visualization and analysis: UCSF ChimeraX visualization system, Protein Sci. 27 (2018), pp. 14–25. doi:10.1002/pro.3235.
   PubMed Web of Science ®Google Scholar
• E. Harder, W. Damm, J. Maple, C. Wu, M. Reboul, J.Y. Xiang, L. Wang, D. Lupyan, M.K. Dahlgren, J.L. Knight, J.W. Kaus, D.S. Cerutti, G. Krilov, W.L. Jorgensen, R. Abel, and R.A. Friesner, OPLS3: A force field providing broad coverage of drug-like small molecules and proteins, J. Chem. Theory Comput. 12 (2016), pp. 281–296. doi:10.1021/acs.jctc.5b00864.
   PubMed Web of Science ®Google Scholar
• T.A. Halgren, R.B. Murphy, R.A. Friesner, H.S. Beard, L.L. Frye, W.T. Pollard, and J.L. Banks, Glide: A new approach for rapid, accurate docking and scoring. 2. enrichment factors in database screening, J. Med. Chem. 47 (2004), pp. 1750–1759. doi:10.1021/jm030644s.
   PubMed Web of Science ®Google Scholar
• R.A. Friesner, R.B. Murphy, M.P. Repasky, L.L. Frye, J.R. Greenwood, T.A. Halgren, P.C. Sanschagrin, and D.T. Mainz, Extra precision Glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein−ligand complexes, J. Med. Chem. 49 (2006), pp. 6177–6196. doi:10.1021/jm051256o.
   PubMed Web of Science ®Google Scholar
• A. Daina, O. Michielin, and V. Zoete, SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, Sci. Rep. 7 (2017), pp. 42717. doi:10.1038/srep42717.
   PubMed Web of Science ®Google Scholar
• D.E.V. Pires, T.L. Blundell, and D.B. Ascher, pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures, J. Med. Chem. 58 (2015), pp. 4066–4072. doi:10.1021/acs.jmedchem.5b00104.
   PubMed Web of Science ®Google Scholar
• P. Banerjee, A.O. Eckert, A.K. Schrey, and R. Preer, ProTox-II: A webserver for the prediction of toxicity of chemicals, Nucleic Acids Res. 46 (2018), pp. W257–W263. doi:10.1093/nar/gky318.
   PubMed Web of Science ®Google Scholar
• G. Xiong, Z. Wu, J. Yi, L. Fu, Z. Yang, C. Hsieh, M. Yin, X. Zeng, C. Wu, A. Lu, X. Chen, T. Hou, and D. Cao, ADMETlab 2.0: An integrated online platform for accurate and comprehensive predictions of ADMET properties, Nucleic Acids Res. 49 (2021), pp. W5–W14. doi:10.1093/nar/gkab255.
   PubMed Web of Science ®Google Scholar
• A.D. Becke, Density-functionalexchange-energy approximation with correct asymptotic behavior, Phys. Rev. A 38 (1988), pp. 3098–3100. doi:10.1103/PhysRevA.38.3098.
   PubMed Web of Science ®Google Scholar
• C. Lee, W. Yang, and R.G. Parr, Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density, Phys. Rev. B. 37 (1988), pp. 785–789. doi:10.1103/PhysRevB.37.785.
   PubMed Web of Science ®Google Scholar
• D.A. Case, I.Y. Ben-Shalom, S.R. Brozell, D.S. Cerutti, T.E. Cheatham III, V.W.D. Cruzeiro, T.A. Darden, R.E. Duke, D. Ghoreishi, M.K. Gilson, H. Gohlke, A.W. Goetz, D. Greene, R. Harris, N. Homeyer, Y. Huang, S. Izadi, A. Kovalenko, T. Kurtzman, T.S. Lee, S. LeGrand, P. Li, C. Lin, J. Liu, T. Luchko, R. Luo, D.J. Mermelstein, K.M. Merz, Y. Miao, G. Monard, C. Nguyen, H. Nguyen, I. Omelyan, A. Onufriev, F. Pan, R. Qi, D.R. Roe, A. Roitberg, C. Sagui, S. Schott-Verdugo, J. Shen, S.L. Simmerling, J. Smith, R. Salomon-Ferrer, J. Swails, R.C. Walker, J. Wang, H. Wei, R.M. Wolf, X. Wu, L. Xiao, D.M. York, and P.A. Kollman, AMBER 2018, Univ. Calif. San Franc (2018).
   Google Scholar
• J.A. Maier, C. Martinez, K. Kasavajhala, L. Wickstrom, K.E. Hauser, and C. Simmerling, ff14SB: Improving the accuracy of protein side chain and backbone parameters from ff99SB, J. Chem. Theory Comput. 11 (2015), pp. 3696–3713. doi:10.1021/acs.jctc.5b00255.
   PubMed Web of Science ®Google Scholar
• J. Wang, R.M. Wolf, J.W. Caldwell, P.A. Kollman, and D.A. Case, Development and testing of a general amber force field, J. Comput. Chem. 25 (2004), pp. 1157–1174. doi:10.1002/jcc.20035.
   PubMed Web of Science ®Google Scholar
• D.J. Price and C.L. Brooks, A modified TIP3P water potential for simulation with Ewald summation, J. Chem. Phys. 121 (2004), pp. 10096–10103. doi:10.1063/1.1808117.
   PubMed Web of Science ®Google Scholar
• V. Kräutler, W.F. van Gunsteren, and P.H. Hünenberger, A fast SHAKE algorithm to solve distance constraint equations for small molecules in molecular dynamics simulations, J. Comput. Chem. 22 (2001), pp. 501–508. doi:10.1002/1096-987X(20010415)22:5<501::AID-JCC1021>3.0.CO;2-V.
   Web of Science ®Google Scholar
• T. Darden, D. York, and L. Pedersen, Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems, J. Chem. Phys. 98 (1993), pp. 10089–10092. doi:10.1063/1.464397.
   Web of Science ®Google Scholar
• R.J. Loncharich, B.R. Brooks, and R.W. Pastor, Langevin dynamics of peptides: The frictional dependence of isomerization rates of N-acetylalanyl-N′-methylamide, Biopolymers 32 (1992), pp. 523–535. doi:10.1002/bip.360320508.
   PubMed Web of Science ®Google Scholar
• H.J.C. Berendsen, J.P.M. Postma, W.F. van Gunsteren, A. DiNola, and J.R. Haak, Molecular dynamics with coupling to an external bath, J. Chem. Phys. 81 (1984), pp. 3684–3690. doi:10.1063/1.448118.
   Web of Science ®Google Scholar
• D.R. Roe and T.E. Cheatham, PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data, J. Chem. Theory Comput. 9 (2013), pp. 3084–3095. doi:10.1021/ct400341p.
   PubMed Web of Science ®Google Scholar
• B.R. Miller, T.D. McGee, J.M. Swails, N. Homeyer, H. Gohlke, and A.E. Roitberg, MMPBSA.py: An efficient program for end-state free energy calculations, J. Chem. Theory Comput. 8 (2012), pp. 3314–3321. doi:10.1021/ct300418h.
   PubMed Web of Science ®Google Scholar
• P.A. Kollman, I. Massova, C. Reyes, B. Kuhn, S. Huo, L. Chong, M. Lee, T. Lee, Y. Duan, W. Wang, O. Donini, P. Cieplak, J. Srinivasan, D.A. Case, and T.E. Cheatham, Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models, Acc. Chem. Res. 33 (2000), pp. 889–897. doi:10.1021/ar000033j.
   PubMed Web of Science ®Google Scholar
• H. Gohlke, C. Kiel, and D.A. Case, Insights into protein–protein binding by binding free energy calculation and free energy decomposition for the Ras–Raf and Ras–RalGDS complexes, J. Mol. Biol. 330 (2003), pp. 891–913. doi:10.1016/S0022-2836(03)00610-7.
   PubMed Web of Science ®Google Scholar
• O. Indari, M.F. Sk, S. Jakhmola, N.A. Jonniya, H.C. Jha, and P. Kar, Decoding the host–parasite protein interactions involved in cerebral malaria through glares of molecular dynamics simulations, J. Phys. Chem. B. 126 (2022), pp. 387–402. doi:10.1021/acs.jpcb.1c07850.
   PubMedGoogle Scholar
• B. Jayaram, Y. Liu, and D.L. Beveridge, A modification of the generalized Born theory for improved estimates of solvation energies and pK shifts, J. Chem. Phys. 109 (1998), pp. 1465–1471. doi:10.1063/1.476697.
   Web of Science ®Google Scholar
• N.A. Jonniya, M.F. Sk, and P. Kar, Characterizing an allosteric inhibitor-induced inactive state in with-no-lysine kinase 1 using Gaussian accelerated molecular dynamics simulations, Phys. Chem. Chem. Phys. 23 (2021), pp. 7343–7358. doi:10.1039/D0CP05733A.
   PubMed Web of Science ®Google Scholar
• S. Jakhmola, N.A. Jonniya, M.F. Sk, A. Rani, P. Kar, and H.C. Jha, Identification of potential inhibitors against Epstein–Barr virus nuclear antigen 1 (EBNA1): An insight from docking and molecular dynamic simulations, ACS Chem. Neurosci. 12 (2021), pp. 3060–3072. doi:10.1021/acschemneuro.1c00350.
   PubMed Web of Science ®Google Scholar
• N.A. Jonniya, M.F. Sk, and P. Kar, Elucidating specificity of an allosteric inhibitor WNK476 among With-No-Lysine kinase isoforms using molecular dynamic simulations, Chem. Biol. Drug Des. 98 (2021), pp. 405–420. doi:10.1111/cbdd.13863.
   PubMed Web of Science ®Google Scholar
• V.H. Masand, M.F. Sk, P. Kar, V. Rastija, and M.E.A. Zaki, Identification of Food Compounds as inhibitors of SARS-CoV-2 main protease using molecular docking and molecular dynamics simulations, Chemom. Intell. Lab Syst. 217 (2021), pp. 104394. doi:10.1016/j.chemolab.2021.104394.
   PubMed Web of Science ®Google Scholar
• S. Singh, M.F. Sk, A. Sonawane, P. Kar, and S. Sadhukhan, Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2 via RNA-dependent RNA polymerase (RdRp) inhibition: An in-silico analysis, J. Biomol. Struct. Dyn. 39 (2021), pp. 6249–6264. doi:10.1080/07391102.2020.1796810.
   PubMed Web of Science ®Google Scholar
• M.F. Sk, N.A. Jonniya, R. Roy, S. Poddar, and P. Kar, Computational investigation of structural dynamics of SARS-CoV-2 methyltransferase-stimulatory factor heterodimer nsp16/nsp10 bound to the cofactor SAM, Front. Mol. Biosci. 7 (2020), pp. 590165. doi:10.3389/fmolb.2020.590165.
   PubMed Web of Science ®Google Scholar
• N.A. Jonniya, M.F. Sk, and P. Kar, Investigating phosphorylation-induced conformational changes in WNK1 kinase by molecular dynamics simulations, ACS Omega 4 (2019), pp. 17404–17416. doi:10.1021/acsomega.9b02187.
   PubMed Web of Science ®Google Scholar
• R. Roy, N.A. Jonniya, S. Poddar, M.F. Sk, and P. Kar, Unraveling the molecular mechanism of recognition of human interferon-stimulated gene product 15 by coronavirus papain-like proteases: A multiscale simulation study, J. Chem. Inf. Model. 61 (2021), pp. 6038–6052. doi:10.1021/acs.jcim.1c00918.
   PubMed Web of Science ®Google Scholar
• M.F. Sk, S. Haridev, R. Roy, and P. Kar, Investigating potency of TMC-126 against wild-type and mutant variants of HIV-1 protease: A molecular dynamics and free energy study, SAR QSAR Environ. Res. 32 (2021), pp. 941–962. doi:10.1080/1062936X.2021.1999318.
   PubMed Web of Science ®Google Scholar
• V. Srimai, M. Ramesh, K. Satya Parameshwar, and T. Parthasarathy, Computer-aided design of selective Cytochrome P450 inhibitors and docking studies of alkyl resorcinol derivatives, Med. Chem. Res. 22 (2013), pp. 5314–5323. doi:10.1007/s00044-013-0532-5.
   Web of Science ®Google Scholar
• Z. Wang, C.E. Hop, K.H. Leung, and J. Pang, Determination of in vitro permeability of drug candidates through a caco-2 cell monolayer by liquid chromatography/tandem mass spectrometry, J. Mass. Spectrom. 35 (2000), pp. 71–76. doi:10.1002/(SICI)1096-9888(200001)35:1<71::AID-JMS915>3.0.CO;2-5.
   PubMed Web of Science ®Google Scholar
• Y. Cao, T. Jiang, and T. Girke, A maximum common substructure-based algorithm for searching and predicting drug-like compounds, Bioinformatics 24 (2008), pp. i366–i374. doi:10.1093/bioinformatics/btn186.
   PubMed Web of Science ®Google Scholar
• T.W.H. Backman, Y. Cao, and T. Girke, ChemMine tools: An online service for analyzing and clustering small molecules, Nucleic Acids Res. 39 (2011), pp. W486–W491. doi:10.1093/nar/gkr320.
   PubMed Web of Science ®Google Scholar
• Y. Cao, A. Charisi, L.C. Cheng, T. Jiang, and T. Girke, ChemmineR: A compound mining framework for R, Bioinformatics 24 (2008), pp. 1733–1734. doi:10.1093/bioinformatics/btn307.
   PubMed Web of Science ®Google Scholar
• M.F. Sk, N.A. Jonniya, R. Roy, and P. Kar, Unraveling the molecular mechanism of recognition of selected next-generation antirheumatoid arthritis inhibitors by Janus kinase 1, ACS Omega 7 (2022), pp. 6195–6209. doi:10.1021/acsomega.1c06715.
   PubMed Web of Science ®Google Scholar
• B.J. Grant, A.P.C. Rodrigues, K.M. ElSawy, J.A. McCammon, and L.S.D. Caves, Bio3d: An R package for the comparative analysis of protein structures, Bioinformatics 22 (2006), pp. 2695–2696. doi:10.1093/bioinformatics/btl461.
   PubMed Web of Science ®Google Scholar
• M.C. Chan, E. Procko, and D. Shukla, Structural rearrangement of the serotonin transporter intracellular gate induced by Thr276 pPhosphorylation, ACS Chem. Neurosci. 13 (2022), pp. 933–945. doi:10.1021/acschemneuro.1c00714.
   PubMedGoogle Scholar
• M.M. Sultan, G. Kiss, and V.S. Pande, Towards simple kinetic models of functional dynamics for a kinase subfamily, Nat. Chem. 10 (2018), pp. 903–909. doi:10.1038/s41557-018-0077-9.
   PubMed Web of Science ®Google Scholar
• C.C. Tsai, Z. Yue, and J. Shen, How electrostatic coupling enables conformational plasticity in a tyrosine kinase, J. Am. Chem. Soc. 141 (2019), pp. 15092–15101. doi:10.1021/jacs.9b06064.
   PubMed Web of Science ®Google Scholar
• H. Möbitz, The ABC of protein kinase conformations, Biochim. Biophys. Acta BBA 1854 (2015), pp. 1555–1566. doi:10.1016/j.bbapap.2015.03.009.
   PubMed Web of Science ®Google Scholar
• Y. Meng, C. Gao, D.K. Clawson, S. Atwell, M. Russell, M. Vieth, and B. Roux, Predicting the conformational variability of Abl tyrosine kinase using molecular dynamics simulations and Markov state models, J. Chem. Theory Comput. 14 (2018), pp. 2721–2732. doi:10.1021/acs.jctc.7b01170.
   PubMed Web of Science ®Google Scholar
• N. Jura, X. Zhang, N.F. Endres, M.A. Seeliger, T. Schindler, and J. Kuriyan, Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms, Mol. Cell. 42 (2011), pp. 9–22. doi:10.1016/j.molcel.2011.03.004.
   PubMed Web of Science ®Google Scholar
• Y. Shan, A. Arkhipov, E.T. Kim, A.C. Pan, and D.E. Shaw, Transitions to catalytically inactive conformations in EGFR kinase, Proc. Natl. Acad. Sci. USA 110 (2013), pp. 7270–7275. doi:10.1073/pnas.1220843110.
   PubMed Web of Science ®Google Scholar
• A.S. Moffett, K.W. Bender, S.C. Huber, and D. Shukla, Molecular dynamics simulations reveal the conformational dynamics of Arabidopsis thaliana BRI1 and BAK1 receptor-like kinases, J. Biol. Chem. 292 (2017), pp. 12643–12652. doi:10.1074/jbc.M117.792762.
   PubMed Web of Science ®Google Scholar
• N.A. Jonniya, M.F. Sk, R. Roy, and P. Kar, Discovery of potential competitive inhibitors against With-No-Lysine kinase 1 for treating hypertension by virtual screening, inverse pharmacophore-based lead optimization, and molecular dynamics simulations, SAR QSAR Environ. Res. 33 (2022), pp. 1–25. doi:10.1080/1062936X.2021.2023218.
   PubMed Web of Science ®Google Scholar
• M.F. Sk, R. Roy, N.A. Jonniya, S. Poddar, and P. Kar, Elucidating biophysical basis of binding of inhibitors to SARS-CoV-2 main protease by using molecular dynamics simulations and free energy calculations, J. Biomol. Struct. Dyn. 39 (2021), pp. 3649–3661. doi:10.1080/07391102.2020.1768149.
   PubMed Web of Science ®Google Scholar
• M.F. Sk, R. Roy, and P. Kar, Exploring the potency of currently used drugs against HIV-1 protease of subtype D variant by using multiscale simulations, J. Biomol. Struct. Dyn. 39 (2021), pp. 988–1003. doi:10.1080/07391102.2020.1724196.
   PubMed Web of Science ®Google Scholar
• P.S. Changelian, M.E. Flanagan, D.J. Ball, C.R. Kent, K.S. Magnuson, W.H. Martin, B.J. Rizzuti, P.S. Sawyer, B.D. Perry, W.H. Brissette, S.P. McCurdy, E.M. Kudlacz, M.J. Conklyn, E.A. Elliott, E.R. Koslov, M.B. Fisher, T.J. Strelevitz, K. Yoon, D.A. Whipple, J. Sun, M.J. Munchhof, J.L. Doty, J.M. Casavant, T.A. Blumenkopf, M. Hines, M.F. Brown, B.M. Lillie, C. Subramanyam, C. Shang-Poa, A.J. Milici, G.E. Beckius, J.D. Moyer, C. Su, T.G. Woodworth, A.S. Gaweco, C.R. Beals, B.H. Littman, D.A. Fisher, J.F. Smith, P. Zagouras, H.A. Magna, M.J. Saltarelli, K.S. Johnson, L.F. Nelms, S.G. Des Etages, L.S. Hayes, T.T. Kawabata, D. Finco-Kent, D.L. Baker, M. Larson, M.S. Si, R. Paniagua, J. Higgins, B. Holm, B. Reitz, Y.J. Zhou, R.E. Morris, J.J. O’Shea, and D.C. Borie, Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor, Science 302 (2003), pp. 875–878. doi:10.1126/science.1087061.
   PubMed Web of Science ®Google Scholar
• A. Mayence and J.J. Vanden Eynde, Baricitinib: A 2018 novel FDA-approved small molecule inhibiting Janus kinases, Pharmaceuticals 12 (2019), pp. 37. doi:10.3390/ph12010037.
   Web of Science ®Google Scholar
• J.L. Wang, L.P. Cheng, T.C. Wang, W. Deng, and F.H. Wu, Molecular modeling study of CP-690550 derivatives as JAK3 kinase inhibitors through combined 3D-QSAR, molecular docking, and dynamics simulation techniques, J. Mol. Graph. Model. 72 (2017), pp. 178–186. doi:10.1016/j.jmgm.2016.12.020.
   PubMed Web of Science ®Google Scholar
• R. Itteboina, S. Ballu, S.K. Sivan, and V. Manga, Molecular docking, 3D QSAR and dynamics simulation studies of imidazo-pyrrolopyridines as janus kinase 1 (JAK 1) inhibitors, Comput. Biol. Chem. 64 (2016), pp. 33–46. doi:10.1016/j.compbiolchem.2016.04.009.
   PubMed Web of Science ®Google Scholar